

Study: ENGOT-ov62/ N-Plus

A Phase II randomized, open label, non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completely debulked advanced HRDpositive high-grade ovarian cancer patients in first line therapy.

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active**
BO	Bologna	Policlinico S. Orsola-Malpighi	Claudio Zamagni	
BS	Brescia	Spedali Civili	Valentina Zizioli	
CA	Cagliari	Policlinico Monserrato	Elena Massa	
LC	Lecco	Ospedale Manzoni	Antonio Ardizzoia	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca	
PI	Pisa	Ospedale Santa Chiara	Carmelo Bengala	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros *	

* MaNGO Principal Investigator

** Activation ongoing